Copyright
©2010 Baishideng.
World J Gastroenterol. Apr 21, 2010; 16(15): 1890-1895
Published online Apr 21, 2010. doi: 10.3748/wjg.v16.i15.1890
Published online Apr 21, 2010. doi: 10.3748/wjg.v16.i15.1890
Table 1 Characteristics of patients with branch duct type IPMN
Total (n = 145) | Resection (n = 33) | Non-resection (n = 112) | |
Age (mean ± SD) (yr) | 66.3 ± 10.2 | 63.9 ± 10.5 | 67.0 ± 10.1 |
NS | |||
Male:female | 79:66 | 20:13 | 59:53 |
NS | |||
Median diameter of cystic lesion (mm) | 20.1 ± 13.0 | 23.8 ± 11.5 | 19 ± 13.3 |
P < 0.05 | |||
Median diameter of MPD (mm) | 2.2 ± 2.3 | 3.6 ± 3.3 | 1.7 ± 1.8 |
P < 0.01 | |||
Median diameter of mural nodule (mm) | 1.6 ± 5.3 | 5.8 ± 9.8 | 0.3 ± 1.6 |
P < 0.01 |
Table 2 Comparison of the branch type IPMN in patients with or without intra- or extra-pancreatic cancer
IPMN with intra- or extra-pancreatic cancer (resection/non-resection) | IPMN without intra- or extra-pancreatic cancer (resection/non-resection) | P value | |
n | 47 (16/31) | 98 (19/79) | |
Age | 68.4 (65.0/70.0) | 65.4 (63.2/66.4) | NS |
Sex (male:female) | 22:25 (7:9/15:16) | 57:41 (13:6/44:35) | NS |
Median diameter of cystic lesion (mm) | 20.8 ± 11.8 (23.3 ± 10.4/19.5 ± 12.4) | 19.7 ± 13.6 (23.0 ± 13.3/19.0 ± 13.7) | NS |
Median diameter of MPD (mm) | 2.2 ± 2.4 (3.5 ± 3.6/1.6 ± 1.2) | 2.1 ± 2.3 (3.6 ± 2.9/1.7 ± 1.9) | NS |
Median diameter of mural nodule (mm) | 2.1 ± 5.7 (5.3 ± 8.7/0.5 ± 1.9) | 1.3 ± 5.1 (5.6 ± 10.5/0.3 ± 1.5) | NS |
Table 3 Incidence of, and detection time, for intra- or extra-pancreatic cancer in patients with IPMN (resected cases)
Neoplasm | Consciousness detection prior IPMN | Simultaneous with detection of carcinoma and IPMN | During follow-up for IPMN | Total |
Gastric cancer | 7 (1) | 3 (3) | 3 (0) | 13 (4) |
Colon cancer | 4 (1) | 4 (0) | 0 | 8 (1) |
Breast cancer | 5 (2) | 0 | 2 (0) | 7 (2) |
Pancreatic cancer | 0 | 5 (4) | 0 | 5 (4) |
Lung cancer | 3 (2) | 1 (1) | 1 (0) | 5 (3) |
Prostate cancer | 2 (0) | 0 | 1 (1) | 3 (1) |
Skin cancer | 2 (1) | 0 | 0 | 2 (1) |
Liver cancer | 1 (0) | 0 | 0 | 1 (0) |
Bile duct cancer | 0 | 0 | 1 (0) | 1 (0) |
Pharyngeal cancer | 1 (0) | 0 | 0 | 1 (0) |
Laryngeal cancer | 1 (1) | 0 | 0 | 1 (1) |
Thyroid cancer | 1 (0) | 0 | 0 | 1 (0) |
Renal cancer | 0 | 1 (1) | 0 | 1 (1) |
Bladder cancer | 1 (1) | 0 | 0 | 1 (1) |
Malignant lymphoma | 1 (0) | 0 | 0 | 1 (0) |
Total | 29 (9) | 14 (9) | 8 (1) | 51 (19) |
Table 4 Details of clinicopathological findings in fatal cases of IPMN
Sex | Age (yr) | Region | Change of cystic lesion (mm) | Change of MPD (mm) | Change of mural nodule (mm) | Resection | Histopathological result | Period from diagnosis (operation) to death (mo) | Cause of death | |
Case 1 | Male | 89 | Head | 60→90 | 10→20 | 10→30 | (-) | Adenocarcinoma (ch+, du+) | 37 | Cancer of death |
Case 2 | Male | 58 | Head | 20→64 | 3→10 | 0→64 | (-) | Adenocarcinoma (ch+, du+) | 112 | Cancer of death |
Case 3 | Male | 53 | Tail | 35 | 1 | 19 | (+) | Invasive ductal carcinoma derived from IPMN (INFα, mpd+) | 15 (14) | Cancer of death |
Case 4 | Female | 58 | Head | 0 | 1 | 26.6 | (+) | Invasive ductal carcinoma derived from IPMN (INFβ, V2, ne1, du+, rp+) | 9 (8) | Cancer of death |
Table 5 Summary of the reports of concomitant extra-pancreatic cancers in patients with IPMN
Author (yr) | Number of IPMN patients | Extra-pancreatic cancers with IPMN patients | Age (mean ± SD) | Male:female | Follow-up period (mo) |
Zhong (1996) | 21 | 5 | NA | NA | NA |
Sugiyama (1999) | 42 | 15 | NA | NA | NA |
Adsay (2002) | 28 | 8 | NA | NA | NA |
Osanai (2003) | 148 | 35 | 70.9 | 31:4 | NA |
Kamisawa (2005) | 79 | 37 | NA | NA | NA |
Eguchi (2006) | 69 | 32 | NA | NA | NA |
Choi (2006) | 61 | 18 | 64.2 ± 8.4 | 13:5 | 65.8 ± 8.5 |
Yoon (2008) | 210 | 77 | 65.3 ± 9.0 | 47:30 | 24.7 |
Ishida (2008) | 61 | 151 | 67.0 ± 7.0 | 12:3 | 50.9 |
Present study | 145 | 422 | 68.3 ± 9.0 | 20:26 | 49.8 ± 42.4 |
Total | 864 | 2843 |
Table 6 Types of cancers reported concomitant with extra-pancreatic cancers in patients with IPMN
Neoplasm | Zhong (1996) | Sugiyama (1999) | Adsay (2002) | Osanai (2003) | Kamisawa (2005) | Egichi (2006) | Choi (2006) | Yoon (2008) | Ishida (2008) | Present study | Total |
Gastric cancer | 0 | 4 | 0 | 8 | 12 | 4 | 8 | 29 | 6 | 13 | 84 |
Colon cancer | 3 | 5 | 0 | 11 | 7 | 8 | 4 | 16 | 4 | 8 | 66 |
Lung cancer | 0 | 1 | 1 | 5 | 4 | 5 | 0 | 3 | 1 | 5 | 25 |
Bile duct cancer | 0 | 1 | 0 | 4 | 1 | NS | 2 | 8 | 1 | 1 | 18 |
Prostate cancer | 0 | 1 | 1 | 2 | 1 | 2 | 0 | 1 | 0 | 3 | 11 |
Renal cancer | 0 | 1 | 1 | 2 | 0 | 2 | 0 | 3 | 1 | 1 | 11 |
Breast cancer | 0 | 1 | 0 | 0 | 2 | NS | 0 | 0 | 0 | 7 | 10 |
Esophageal cancer | 2 | 0 | 0 | 2 | 4 | NS | 0 | 0 | 1 | 0 | 9 |
Malignant lymphoma | 0 | 0 | 0 | 0 | 1 | NS | 2 | 4 | 1 | 1 | 9 |
Bladder cancer | 0 | 1 | 1 | 0 | 0 | 2 | 1 | 1 | 0 | 1 | 7 |
Liver cancer | 0 | 0 | 0 | 1 | 2 | NS | 0 | 1 | 1 | 1 | 6 |
Thyroid cancer | 0 | 0 | 0 | 0 | 0 | NS | 1 | 3 | 0 | 1 | 5 |
Ampullary cancer | 0 | 0 | 1 | 0 | 0 | NS | 0 | 3 | 1 | 0 | 5 |
Skin cancer | 0 | 0 | 1 | 0 | 0 | NS | 0 | 1 | 0 | 2 | 4 |
Uterine cancer | 0 | 0 | 0 | 0 | 1 | NS | 0 | 2 | 0 | 0 | 3 |
Laryngeal cancer | 0 | 0 | 0 | 0 | 1 | NS | 0 | 0 | 0 | 1 | 2 |
Pharyngeal cancer | 0 | 0 | 0 | 0 | 1 | NS | 0 | 0 | 0 | 1 | 2 |
Ovarian cancer | 0 | 0 | 0 | 0 | 0 | NS | 0 | 1 | 0 | 0 | 1 |
Duodenal cancer | 0 | 0 | 0 | 0 | 0 | NS | 0 | 1 | 0 | 0 | 1 |
Other cancer or unknown | 0 | 0 | 2 | 0 | 0 | 9 | 0 | 0 | 0 | 0 | 11 |
Total | 5 | 15 | 8 | 35 | 37 | 32 | 18 | 77 | 17 | 46 | 290 |
- Citation: Ikeuchi N, Itoi T, Sofuni A, Itokawa F, Tsuchiya T, Kurihara T, Ishii K, Tsuji S, Umeda J, Moriyasu F, Tsuchida A, Kasuya K. Prognosis of cancer with branch duct type IPMN of the pancreas. World J Gastroenterol 2010; 16(15): 1890-1895
- URL: https://www.wjgnet.com/1007-9327/full/v16/i15/1890.htm
- DOI: https://dx.doi.org/10.3748/wjg.v16.i15.1890